Skip to main content

Table 4 Univariate analysis of the different variablesa

From: Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers

  

RFS

OS

Variable

Number of patients

Events

5-year RFS

HR (95% CI)

Events

5-year OS

HR (95% CI)

T

       

   1

35

8

74.2

1

6

84.2

1

   2

46

15

65.9

1.51 (0.64 to 3.58)

10

74.3

1.30 (0.47 to 3.60)

   3 or 4

5

2

53.3

2.15 (0.45 to 10.4)

1

80.0

1.34 (0.16 to 11.3)

  

P = 0.510*

P = 0.868*

N

       

   N-

35

4

88.1

1

2

94.2

1

   N+

51

21

55.8

3.94 (1.35 to 11.5)

15

70.0

4.89 (1.12 to 21.4)

  

P = 0.007*

P = 0.020*

SBR

       

   2

36

5

84.9

1

4

89.4

1

   3

49

20

55.8

3.80 (1.42 to 10.2)

13

70.8

2.96 (0.96 to 9.15)

  

P = 0.004*

P = 0.048*

ER

       

   ER-

60

19

66.9

1

13

76.2

1

   ER+

26

6

70.1

0.64 (0.25 to 1.60)

4

84.9

0.68 (0.22 to 2.10)

  

P = 0.333*

P = 0.505*

PR

       

   PR-

44

18

57.6

1

13

67.3

1

   PR+

42

7

80.9

0.36 (0.15 to 0.87)

4

92.4

0.32 (0.10 to 0.99)

  

P = 0.018*

P = 0.037*

ER/PR

       

   ER-/PR-

42

17

58.7

1

12

68.9

1

   Other

44

8

78.2

0.39 (0.17 to 0.91)

5

89.2

0.40 (0.14 to 1.14)

  

P = 0.024*

P = 0.076*

MED1

       

   Del/Nm

30

10

66.2

1

7

72.9

1

   Amp

56

15

70.0

0.76 (0.34 to 1.70)

10

82.5

0.63 (0.23 to 1.69)

  

P = 0.507*

P = 0.354*

STARD3

       

   Del/Nm

6

2

55.6

1

2

53.3

1

   Amp

80

23

69.4

0.85 (0.20 to 3.62)

15

80.9

0.48 (0.11 to 2.14)

  

P = 0.826*

P = 0.327*

GRB7

       

   Del/Nm

2

1

50.0

1

1

0.00

1

   Amp

84

24

69.3

0.30 (0.04 to 2.33)

16

80.1

0.15 (0.02 to 1.20)

  

P = 0.225*

P = 0.038*

THRA

       

   Del/Nm

39

16

59.0

1

11

73.8

1

   Amp

47

9

79.3

0.50 (0.22 to 1.13)

6

84.7

0.53 (0.19 to 1.43)

  

P = 0.090*

P = 0.199*

RARA

       

   Del/Nm

63

21

64.1

1

15

75.2

1

   Amp

23

4

82.4

0.50 (0.17 to 1.45)

2

91.3

0.36 (0.08 to 1.59)

  

P = 0.190*

P = 0.162*

TOP2A

       

   Del/Nm

63

21

63.7

1

15

74.8

1

   Amp

23

4

82.4

0.47 (0.16 to 1.38)

2

91.3

0.34 (0.08 to 1.48)

  

P = 0.159*

P = 0.132*

IGFBP4

       

   Del/Nm

68

21

66.6

1

15

76.9

1

   Amp

18

4

77.4

0.70 (0.24 to 2.06)

2

88.9

0.49 (0.11 to 2.16)

  

P = 0.520*

P = 0.335*

CCR7

       

   Del/Nm

68

21

67.0

1

16

75.3

1

   Amp

18

4

75.4

0.66 (0.22 to 1.93)

1

94.4

0.21 (0.03 to 1.61)

  

P = 0.442*

P = 0.099*

KRT20

       

   Del/Nm

74

21

69.2

1

15

78.8

1

   Amp

12

4

66.7

1.31 (0.45 to 3.81)

2

81.5

1.02 (0.23 to 4.49)

  

P = 0.622*

P = 0.981*

KRT19

       

   Del/Nm

76

23

67.6

1

16

78.3

1

   Amp

10

2

78.7

0.70 (0.16 to 2.96)

1

90.0

0.64 (0.08 to 4.82)

  

P = 0.624*

P = 0.658*

GAS

       

   Del/Nm

80

24

68.0

1

16

79.1

1

   Amp

6

1

83.3

0.64 (0.09 to 4.74)

1

83.3

1.21 (0.16 to 9.20)

  

P = 0.660*

P = 0.852*

ER-/PR- and TOP2A Del/Nm

30

15

49.2

1

11

61.0

1

Others

56

10

79.2

0.29 (0.13 to 0.65)

6

89.7

0.28 (0.10 to 0.76)

  

P = 0.001*

P = 0.008*

  1. aT, tumor size; N, lymph node status; SBR grade, Scarff-Bloom-Richardson histological grade; ER, estrogen receptor; PR, progesterone receptor; Del, deletion; Nm, normal; Amp, amplification; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; MED1, mediator complex subunit 1 gene; STARD3, steroidogenic acute regulatory-related lipid transfer (START) domain containing 3 gene; HER2, human epidermal growth factor receptor 2 gene; GRB7, growth factor receptor-bound protein 7 gene; THRA, thyroid hormone receptor α gene; RARA, retinoic acid receptor α gene; TOP2A, topoisomerase IIα gene; IGFBP4, insulin-like growth factor-binding protein 4 gene; CCR7, C-C chemokine receptor type 7 gene; KRT20, cytokeratin 20 gene; KRT19, cytokeratin 19 gene; GAS, gastrin gene; SSTR2, somatostatin receptor type II gene; *log-rank test.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us